FDA advisors endorse weight-loss drug Qnexa

FDA advisors endorse weight-loss drug Qnexa

FDA advisors endorse weight-loss drug Qnexa

FDA advisors endorse weight-loss drug Qnexa

U.S. reviewers said proponents of a new drug for obesity of Vivus Inc. on Wednesday that outweigh the benefits for the health of the risks of birth defects of the heart and the drug.

A panel of external experts in the food and Drug Administration later Wednesday if it recommends the adoption of votes which would be the first new drug prescribed for obesity in 13 years.

The FDA rejected for security reasons in 2010 of Qnexa Vivus first, along with the other two pills that are also looking for a second round of review of obesity.

Usually follows the FDA Panel recommendations, although it is not mandatory. It will take a final decision of 17 April.

Phentermine appetite suppressors and anti-seizure drug Qnexa, Topiramate, which combines helped patients lose at least 10 percent of their weight after a year of treatment, the company said.

FDA advisors endorse weight-loss drug Qnexa

One of the main causes of obesity, diabetes, cardiovascular diseases and other serious health problems, has the United States, epidemic proportions with close to a third of the population is obese and overweight who managed more than half.

“In medical school, I was taught that if the risk of not treating the condition is greater than the risk of the treatment of the same, have to deal with,” said Dr. Arya Sharma, a Chair in the obesity research at the University of Alberta in Canada and paid Vivus Advisor.